RLM.L Regulatory News (RLM)

23 Jan 2008 07:00

PuriCore Plc23 January 2008 PuriCore's Sterilox Solution Highly Effective Against Pandemic H5N1 Avian Influenza MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 23 January 2008 - PuriCore (LSE: PURI),the life sciences company focused on the control of infectious pathogens withits novel, safe antimicrobial technology, announces that its Sterilox Solutionhas been proven highly effective against pandemic H5N1 avian influenza, a highlycontagious and lethal outbreak pathogen. The research showed that SteriloxSolution completely inactivated the H5N1 test strain and passed the USEnvironmental Protection Agency's recommended hard-surface disinfection test,which requires two-minutes contact time. The study conducted by ATS Labs, an independent certified laboratory, tested thevirucidal activity of the Sterilox Solution in decontaminating H5N1 avianinfluenza on hard surfaces. Previous PuriCore studies proved the effectivenessof Sterilox Solution against a common surrogate for the pandemic H5N1 avianinfluenza strain, the human influenza virus, A/Hong Kong 68 Strain. This newH5N1 research builds upon PuriCore's earlier microbiological research, includingpublished studies last year showing the effectiveness of the Sterilox Solutionagainst major outbreak pathogens such as norovirus, MRSA, and acinetobacter. The Sterilox Solution mimics the natural anti-microbial hypochlorous acidproduced by the human body to fight pathogens. A wide range of markets thatdepend upon controlling the spread of infectious pathogens-including food retailand foodservice, hospitality, medical device disinfection, and wound therapy-useSterilox Systems. Greg Bosch, Chief Executive of PuriCore, said: "Pandemic avian influenza remains a concern for healthcare providers,governments, and the general population. These study results further demonstratethat our safe and environmentally friendly Sterilox Solution is highly effectiveagainst H5N1 and other dangerous pathogens and can be used in a variety ofsettings including hotels, hospitals, schools, and cruise ships." Enquiries:Ben Brewerton Greg Bosch, CEOSusan Quigley Keith A. Goldan, CFOFinancial Dynamics PuriCore+44 (0) 20 7831 3113 +1 484 321 2700 About PuriCore PuriCore plc (LSE: PURI) is a life sciences company focused on developing andcommercialising proprietary products that safely, effectively, and naturallykill contagious pathogens. PuriCore's technology provides a solution to a broadrange of markets that depend upon controlling contamination, including foodsafety in retail and foodservice, medical device disinfection, wound therapy,and hospitality. The Company's proprietary technology mimics the human body'sproduction of the natural antimicrobial hypochlorous acid, which is highlyeffective in killing bacteria, viruses, and fungal spores. Deployinghypochlorous acid solutions as soaks, sprays, mists, and in other forms,PuriCore's technology is designed to limit the spread of infectious disease,including major public health threats of M. tuberculosis, MRSA, E.coli,Norovirus, Avian Influenza, HIV, Polio Virus, Helicobater pylori, andLegionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices inStafford, UK. To receive additional information on PuriCore, please visit our website atwww.puricore.com, which does not form part of this press release. Certain statements made in this announcement are forward-looking statements.These forward-looking statements are not historical facts but rather are basedon the Company's current expectations, estimates, and projections about itsindustry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,''intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressionsare intended to identify forward-looking statements. These statements are notguarantees of future performance and are subject to known and unknown risks,uncertainties, and other factors, some of which are beyond the Company'scontrol, are difficult to predict, and could cause actual results to differmaterially from those expressed or forecasted in the forward-looking statements.The Company cautions shareholders and prospective shareholders not to placeundue reliance on these forward-looking statements, which reflect the view ofthe Company only as of the date of this announcement. The forward-lookingstatements made in this announcement relate only to events as of the date onwhich the statements are made. The Company will not undertake any obligation torelease publicly any revisions or updates to these forward-looking statements toreflect events, circumstances, or unanticipated events occurring after the dateof this announcement except as required by law or by any appropriate regulatoryauthority. This information is provided by RNS The company news service from the London Stock Exchange